Gillian C. Ivers-Read
Net Worth

Last updated:

What is Gillian C. Ivers-Read net worth?

The estimated net worth of Dr. Gillian C. Ivers-Read is at least $13,956,357 as of 2 Sep 2022. He owns shares worth $23,460 as insider, has earned $3,545,737 from insider trading and has received compensation worth at least $10,387,160 in Clovis Oncology, Inc..

What is the salary of Gillian C. Ivers-Read?

Dr. Gillian C. Ivers-Read salary is $741,940 per year as Co-Founder, Chief Regulatory Officer & Executive Vice President of Technical Operations in Clovis Oncology, Inc..

How old is Gillian C. Ivers-Read?

Dr. Gillian C. Ivers-Read is 71 years old, born in 1954.

What stocks does Gillian C. Ivers-Read currently own?

As insider, Dr. Gillian C. Ivers-Read owns shares in one company:

Company Title Shares Price per share Total value
Clovis Oncology, Inc. (CLVS) Co-Founder, Chief Regulatory Officer & Executive Vice President of Technical Operations 288,919 $0.08 $23,460

What does Clovis Oncology, Inc. do?

Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, as well as for metastatic castration-resistant prostate cancer. In Europe, the company offers Rubraca for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. It is also developing lucitanib, an investigational angiogenesis inhibitor, which inhibits vascular endothelial growth factor receptors 1 through 3 (VEGFR 1-3), platelet-derived growth factor receptors alpha and beta (PDGFRa/ß), and fibroblast growth factor receptors 1 through 3 (FGFR 1-3);and FAP-2286, an investigational peptide-targeted radionuclide therapy and imaging agent targeting fibroblast activation protein. In addition, the company sells its Rubraca through a limited number of specialty distributor and specialty pharmacy providers, who subsequently sells Rubraca to patients and health care providers. Clovis Oncology, Inc. has license agreements with Pfizer Inc., AstraZeneca UK Limited, Advenchen Laboratories LLC, and 3B Pharmaceuticals GmbH, a clinical collaboration with Bristol Myers Squibb Company; and a partnership with Foundation Medicine, Inc. Clovis Oncology, Inc. was incorporated in 2009 and is headquartered in Boulder, Colorado. On December 11, 2022, Clovis Oncology, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

CLVS logo
CLVS
Clovis Oncology, Inc.
$0.08

Gillian C. Ivers-Read insider trading

Clovis Oncology, Inc.

Dr. Gillian C. Ivers-Read has made 57 insider trades between 2011-2022, according to the Form 4 filled with the SEC. Most recently he sold 2,234 units of CLVS stock worth $2,681 on 2 Sep 2022.

The largest trade he's ever made was exercising 68,965 units of CLVS stock on 10 Dec 2020. As of 2 Sep 2022 he still owns at least 288,919 units of CLVS stock.

Transaction Date Security Shares Price per share Total value Source
Sale
Common Stock 2,234 $1.2 $2,681
Option
Restricted Stock Units 5,063 N/A N/A
Option
Common Stock 5,063 N/A N/A
Sale
Common Stock 2,100 $1.46 $3,068
Option
Restricted Stock Units 4,625 N/A N/A
Sale
Common Stock 1,702 $1.46 $2,487
Option
Restricted Stock Units 3,749 N/A N/A
Option
Common Stock 3,749 N/A N/A
Option
Common Stock 4,625 N/A N/A
Sale
Common Stock 2,327 $0.64 $1,494
Option
Restricted Stock Units 5,062 N/A N/A
Option
Common Stock 5,062 N/A N/A
Sale
Common Stock 1,671 $1.97 $3,292
Sale
Common Stock 2,062 $1.97 $4,062
Option
Restricted Stock Units 4,625 N/A N/A
Option
Restricted Stock Units 3,749 N/A N/A
Option
Common Stock 3,749 N/A N/A
Option
Common Stock 4,625 N/A N/A
Option
Restricted Stock Units 20,250 N/A N/A
Sale
Common Stock 10,416 $1.87 $19,436
Sale
Common Stock 354 $1.87 $661
Option
Restricted Stock Units 688 N/A N/A
Option
Common Stock 688 N/A N/A
Option
Common Stock 20,250 N/A N/A
Sale
Common Stock 2,453 $1.94 $4,759
Option
Restricted Stock Units 4,625 N/A N/A
Sale
Common Stock 1,989 $1.94 $3,859
Option
Restricted Stock Units 3,750 N/A N/A
Option
Common Stock 8,375 N/A N/A
Option
Restricted Stock Units 687 N/A N/A
Sale
Common Stock 304 $3 $912
Option
Common Stock 687 N/A N/A
Sale
Common Stock 3,696 $4.55 $16,817
Option
Restricted Stock Units 8,374 N/A N/A
Option
Common Stock 8,374 N/A N/A
Sale
Common Stock 304 $4.89 $1,487
Option
Restricted Stock Units 688 N/A N/A
Option
Common Stock 688 N/A N/A
Sale
Common Stock 3,683 $4.82 $17,752
Option
Restricted Stock Units 8,374 N/A N/A
Option
Common Stock 8,374 N/A N/A
Sale
Common Stock 283 N/A N/A
Option
Restricted Stock Units 687 N/A N/A
Option
Common Stock 687 N/A N/A
Sale
Common Stock 3,952 $5.54 $21,894
Sale
Common Stock 3,952 $5.54 $21,894
Option
Restricted Stock Units 8,374 N/A N/A
Option
Common Stock 8,374 N/A N/A
Option
Common Stock 8,374 N/A N/A
Sale
Common Stock 580 N/A N/A
Sale
Common Stock 580 $6.29 $3,648
Option
Common Stock 1,313 N/A N/A
Option
Restricted Stock Units 1,313 N/A N/A
Option
Restricted Stock Units 1,313 N/A N/A
Option
Common Stock 1,313 N/A N/A
Sale
Common Stock 10,990 $7.97 $87,590
Sale
Common Stock 10,990 $7.97 $87,590
Option
Common Stock 22,250 N/A N/A
Option
Restricted Stock Units 22,250 N/A N/A
Option
Common Stock 1,875 N/A N/A
Option
Restricted Stock Units 1,875 N/A N/A
Sale
Common Stock 829 $5.68 $4,709
Option
Common Stock 68,965 $3.28 $226,205
Option
Employee Stock Option (right to buy) 68,965 $3.28 $226,205
Option
Common Stock 1,312 N/A N/A
Sale
Common Stock 581 $4.89 $2,841
Option
Restricted Stock Units 1,312 N/A N/A
Option
Common Stock 3,749 N/A N/A
Sale
Common Stock 1,689 $4.93 $8,327
Option
Restricted Stock Units 3,749 N/A N/A
Option
Common Stock 1,875 N/A N/A
Sale
Common Stock 838 $6.86 $5,744
Option
Restricted Stock Units 1,875 N/A N/A
Sale
Common Stock 553 $5.3 $2,931
Option
Common Stock 1,313 N/A N/A
Option
Restricted Stock Units 1,313 N/A N/A
Option
Common Stock 3,749 N/A N/A
Option
Restricted Stock Units 3,749 N/A N/A
Sale
Common Stock 1,670 $5.92 $9,886
Option
Common Stock 1,875 N/A N/A
Option
Restricted Stock Units 1,875 N/A N/A
Sale
Common Stock 829 $6.74 $5,587
Option
Restricted Stock Units 1,312 N/A N/A
Option
Common Stock 1,312 N/A N/A
Sale
Common Stock 598 $7.03 $4,204
Sale
Common Stock 1,475 $8.1 $11,948
Option
Common Stock 3,749 N/A N/A
Option
Restricted Stock Units 3,749 N/A N/A
Option
Common Stock 1,875 N/A N/A
Option
Restricted Stock Units 1,875 N/A N/A
Sale
Common Stock 829 $4.6 $3,813
Option
Restricted Stock Units 1,313 N/A N/A
Sale
Common Stock 605 $7.2 $4,356
Option
Common Stock 1,313 N/A N/A
Option
Restricted Stock Units 14,997 N/A N/A
Option
Common Stock 14,997 N/A N/A
Sale
Common Stock 7,204 $8.41 $60,586
Option
Restricted Stock Units 1,875 N/A N/A
Option
Common Stock 1,875 N/A N/A
Sale
Common Stock 830 $11.3 $9,379
Option
Common Stock 1,312 N/A N/A
Option
Restricted Stock Units 1,312 N/A N/A
Sale
Common Stock 592 $14.6 $8,640
Option
Common Stock 1,875 N/A N/A
Sale
Common Stock 837 $4.8 $4,018
Option
Restricted Stock Units 1,875 N/A N/A
Option
Restricted Stock Units 1,313 N/A N/A
Sale
Common Stock 630 $5.21 $3,282
Option
Common Stock 1,313 N/A N/A
Option
Common Stock 1,875 N/A N/A
Option
Restricted Stock Units 1,875 N/A N/A
Sale
Common Stock 829 $14.7 $12,186
Sale
Common Stock 577 $15.07 $8,695
Option
Restricted Stock Units 1,312 N/A N/A
Option
Common Stock 1,312 N/A N/A
Option
Restricted Stock Units 1,875 N/A N/A
Sale
Common Stock 830 $26.13 $21,688
Option
Common Stock 1,875 N/A N/A
Sale
Common Stock 1,611 $29.29 $47,186
Option
Common Stock 625 N/A N/A
Option
Common Stock 3,375 N/A N/A
Option
Restricted Stock Units 3,375 N/A N/A
Option
Restricted Stock Units 1,875 N/A N/A
Sale
Common Stock 829 $17.72 $14,690
Option
Common Stock 1,875 N/A N/A
Option
Restricted Stock Units 625 N/A N/A
Sale
Common Stock 250 $21.23 $5,308
Option
Common Stock 625 N/A N/A
Option
Common Stock 1,875 N/A N/A
Option
Restricted Stock Units 1,875 N/A N/A
Option
Common Stock 625 N/A N/A
Option
Restricted Stock Units 625 N/A N/A
Option
Restricted Stock Units 1,875 N/A N/A
Option
Common Stock 1,875 N/A N/A
Option
Restricted Stock Units 625 N/A N/A
Option
Common Stock 625 N/A N/A
Option
Restricted Stock Units 1,875 N/A N/A
Option
Common Stock 1,875 N/A N/A
Option
Restricted Stock Units 2,500 N/A N/A
Option
Common Stock 2,500 N/A N/A
Sale
Common Stock 3,000 $54.09 $162,270
Sale
Common Stock 3,000 $59.16 $177,480
Option
Common Stock 7,500 N/A N/A
Option
Restricted Stock Units 7,500 N/A N/A
Sale
Common Stock 3,000 $64.16 $192,480
Sale
Common Stock 3,000 $63.7 $191,100
Sale
Common Stock 3,000 $84.54 $253,620
Sale
Common Stock 3,000 $69.5 $208,500
Sale
Common Stock 3,000 $70.05 $210,150
Sale
Common Stock 3,000 $91.56 $274,680
Sale
Common Stock 3,000 $61.82 $185,460
Sale
Common Stock 3,000 $47.39 $142,170
Sale
Common Stock 3,000 $56.02 $168,060
Sale
Common Stock 3,000 $66.99 $200,970
Sale
Common Stock 3,000 $91.91 $275,730
Sale
Common Stock 3,000 $112.56 $337,680
Purchase
Common Stock 5,323 $13 $69,199

Clovis Oncology key executives

Clovis Oncology, Inc. executives and other stock owners filed with the SEC:

  • Dr. Gillian C. Ivers-Read (71) Co-Founder, Chief Regulatory Officer & Executive Vice President of Technical Operations
  • Dr. Lindsey Rolfe B.Sc., BSc, MB ChB, MRCP, FFPM (57) Executive Vice President of Clinical Devel. & Pharmacovigilance and Chief Medical Officer
  • Mr. Daniel W. Muehl (61) Executive Vice President & Chief Financial Officer
  • Mr. Patrick J. Mahaffy (62) Co-Founder, Chief Executive Officer, Pres & Executive Director
  • Mr. Paul Edward Gross (60) Executive Vice President, Gen. Counsel & Sec.